ATE347908T1 - Vorbeugung von gewebeadhäsion - Google Patents

Vorbeugung von gewebeadhäsion

Info

Publication number
ATE347908T1
ATE347908T1 AT03702560T AT03702560T ATE347908T1 AT E347908 T1 ATE347908 T1 AT E347908T1 AT 03702560 T AT03702560 T AT 03702560T AT 03702560 T AT03702560 T AT 03702560T AT E347908 T1 ATE347908 T1 AT E347908T1
Authority
AT
Austria
Prior art keywords
post
operative
adhesions
prevention
formation
Prior art date
Application number
AT03702560T
Other languages
English (en)
Inventor
Philippe Koninckx
Peter Carmeliet
Desire Collen
Sanabria Carlos Roger Molinas
Original Assignee
Vlaams Interuniv Inst Biotech
Thromb X
Leuven K U Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201983A external-priority patent/GB2384428A/en
Priority claimed from GB0202379A external-priority patent/GB2384706A/en
Priority claimed from GB0225128A external-priority patent/GB0225128D0/en
Application filed by Vlaams Interuniv Inst Biotech, Thromb X, Leuven K U Res & Dev filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE347908T1 publication Critical patent/ATE347908T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
AT03702560T 2002-01-29 2003-01-29 Vorbeugung von gewebeadhäsion ATE347908T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201983A GB2384428A (en) 2002-01-29 2002-01-29 Inhibitors of HIF
GB0202379A GB2384706A (en) 2002-02-04 2002-02-04 Agent for the prevention or minimisation of post-operative adhesion formation and/or cell implantation
GB0225128A GB0225128D0 (en) 2002-10-29 2002-10-29 Laparoscopy and adhesion formation

Publications (1)

Publication Number Publication Date
ATE347908T1 true ATE347908T1 (de) 2007-01-15

Family

ID=27669901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702560T ATE347908T1 (de) 2002-01-29 2003-01-29 Vorbeugung von gewebeadhäsion

Country Status (5)

Country Link
US (1) US20050163781A1 (de)
EP (1) EP1482975B1 (de)
AT (1) ATE347908T1 (de)
DE (1) DE60310383T2 (de)
WO (1) WO2003063904A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20050049309A1 (en) * 2003-07-14 2005-03-03 Lynn Kirkpatrick Regulation of HIF protein levels via deubiquitination pathway
CA2551100A1 (en) 2003-12-23 2005-07-14 The Trustees Of The University Of Pennsylvania Compositions and methods for combined therapy of disease
WO2006026485A2 (en) * 2004-08-25 2006-03-09 Isis Pharmaceuticals, Inc. Modulation of hif1-beta expression
CN101184776B (zh) 2005-03-24 2013-04-24 斯路姆基因公司 新型抗胎盘生长因子抗体
US20080241270A1 (en) * 2007-03-30 2008-10-02 Neal Robert A Fluid composition for inhibiting surgical adhesion formation and related method of production
ES2462416T3 (es) * 2007-08-06 2014-05-22 Senju Pharmaceutical Co., Ltd. Producto farmacéutico que contiene un inhibidor de la expresión de HIF-1 alfa y HIF-2 alfa
EP2785739B1 (de) 2011-12-01 2017-03-15 ThromboGenics N.V. Verbesserung eines augendrucksenkungsergebnisses
CA2932465C (en) 2013-12-18 2023-08-22 Csl Limited Methods of treating wounds in a diabetic subject
US20190031762A1 (en) 2016-03-10 2019-01-31 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
EP3448421B1 (de) * 2016-04-29 2021-11-03 The Board of Trustees of the Leland Stanford Junior University Verfahren und zusammensetzungen zur vorbeugung und behandlung von chirurgischen verklebungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887076A3 (de) * 1997-05-07 1999-03-31 Saturnus A.G. Verhinderung von Gewebeverklebung und ein dafür vorgesehenes endoskopisches System zum Aufblasen einer Körperhöhle
TW557297B (en) * 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
PL203782B1 (pl) * 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation

Also Published As

Publication number Publication date
WO2003063904A2 (en) 2003-08-07
EP1482975B1 (de) 2006-12-13
US20050163781A1 (en) 2005-07-28
WO2003063904A3 (en) 2004-01-15
EP1482975A2 (de) 2004-12-08
DE60310383T2 (de) 2007-09-20
DE60310383D1 (de) 2007-01-25

Similar Documents

Publication Publication Date Title
DE60310383D1 (de) Vorbeugung von gewebeadhäsion
DE60313624D1 (de) Derivate von heteroarylnitrilverbindungen
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
NO20055305L (no) Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
ATE464889T1 (de) Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BRPI0311323B8 (pt) composto inibidor de c-aril glicosídeo sglt2, composição farmacêutica e combinação
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
DE69839877D1 (de) Behandlung und vorbeugung von adhesionen
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
ATE384058T1 (de) Thiazolderivate
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
DE60232173D1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
IN2005KO00312A (de)
EA200501513A1 (ru) Замещённые 1, 4 - диазепины и их применения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties